Get the Stockscreener App
6.00
2.28%
-0.14
After Hours:
6.12
0.12
+2.00%
Evolus Inc stock is traded at $6.00, with a volume of 1.14M.
It is down -2.28% in the last 24 hours and down -16.55% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$6.14
Open:
$6.15
24h Volume:
1.14M
Relative Volume:
0.84
Market Cap:
$388.11M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-5.5556
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-6.69%
1M Performance:
-16.55%
6M Performance:
-37.11%
1Y Performance:
-64.50%
1-Day Range:
$5.97
$6.17
1-Week Range:
$5.92
$6.46
52-Week Range:
$5.71
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.00 | 397.17M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
How to build a custom watchlist for Evolus Inc.Weekly Investment Recap & Entry Point Confirmation Signals - newser.com
Evolus Inc. stock trend forecastJuly 2025 Setups & Risk Managed Investment Signals - newser.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Equities Analysts Offer Predictions for Evolus Q3 Earnings - MarketBeat
What institutional flow reveals about Evolus Inc.2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Real time alert setup for Evolus Inc. performanceRisk Management & Weekly Chart Analysis and Guides - newser.com
Volume spikes in Evolus Inc. stock – what they meanJuly 2025 Macro Moves & Stepwise Trade Signal Implementation - newser.com
Is Evolus Inc. trending in predictive chart models2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Can Evolus Inc. recover in the next quarterGDP Growth & AI Forecast Swing Trade Picks - newser.com
Evolus Inc. stock daily chart insightsMarket Growth Review & AI Driven Price Forecasts - newser.com
Using portfolio simulators with Evolus Inc. included2025 Top Decliners & Verified Stock Trade Ideas - newser.com
Is Evolus Inc. (EVL) stock good for wealth creationMarket Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
Jeffrey Plumer: Adding to the Legal Toolkit - Orange County Business Journal
Will Evolus Inc. (EVL) stock split increase liquidityWeekly Stock Report & Real-Time Sentiment Analysis - newser.com
Analyzing QuidelOrtho (NASDAQ:QDEL) and Evolus (NASDAQ:EOLS) - Defense World
Is Evolus Inc. meeting your algorithmic filter criteria2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Price momentum metrics for Evolus Inc. explainedMarket Growth Review & AI Driven Stock Reports - newser.com
What analysts say about Evolus Inc stockStock Buyback Announcements & Capitalize On Momentum - earlytimes.in
Is Evolus Inc. (EVL) stock a buy for dividend portfoliosWeekly Trade Summary & AI Optimized Trading Strategy Guides - newser.com
Midday Stock Roundup: Clean Energy Fuels Corp. Up Nearly 6% - Orange County Business Journal
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $19 - 富途牛牛
Assenagon Asset Management S.A. Sells 98,325 Shares of Evolus, Inc. $EOLS - MarketBeat
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consu - GuruFocus
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch - Nasdaq
Revolutionary Cold-X Technology: Evolus Partners with Top Miami Surgeon for Groundbreaking Filler Launch - Stock Titan
Evolus, Inc. $EOLS Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Risks Report: Whats the beta of Evolus Inc stockTrade Analysis Report & Real-Time Market Sentiment Alerts - خودرو بانک
Returns Recap: Is Evolus Inc a strong candidate for buy and holdTrade Volume Summary & Safe Capital Allocation Plans - khodrobank.com
While shareholders of Evolus (NASDAQ:EOLS) are in the black over 5 years, those who bought a week ago aren't so fortunate - Yahoo Finance
Highs Report: What are Evolus Inc.’s earnings expectationsEarnings Miss & Verified Short-Term Trading Plans - خودرو بانک
Growth Recap: How does Evolus Inc. correlate with NasdaqJuly 2025 Volume & Capital Protection Trade Alerts - خودرو بانک
Volume Report: What analysts say about Flag Ship Acquisition Corporation stockQuarterly Risk Review & Short-Term Swing Trade Alerts - khodrobank.com
Downgrade Watch: What is the earnings history of Evolus IncWeekly Market Report & Growth Focused Investment Plans - khodrobank.com
Merger Talk: What analysts say about Evolus Inc stockMarket Volume Summary & Low Risk High Win Rate Stock Picks - khodrobank.com
Quarterly Trades: What hedge funds are buying Evolus IncExit Point & Technical Buy Zone Confirmations - خودرو بانک
Analyst Calls: Is Evolus Inc undervalued by DCF analysis2025 Buyback Activity & Free Reliable Trade Execution Plans - khodrobank.com
Sentiment Watch: Is Evolus Inc. stock trending bullishDollar Strength & Breakout Confirmation Alerts - خودرو بانک
Treasury Yields: Is Evolus Inc showing insider buyingJuly 2025 Movers & Low Risk High Reward Trade Ideas - خودرو بانک
Evolus, Inc. (NASDAQ:EOLS): When Will It Breakeven? - simplywall.st
Meme Stocks: How does Evolus Inc correlate with NasdaqWeekly Trend Report & Expert Curated Trade Setup Alerts - خودرو بانک
Volume Report: Is EverCommerce Inc affected by consumer sentimentQuarterly Profit Summary & Reliable Breakout Forecasts - خودرو بانک
Gap Down: What analysts say about Evolus Inc stockSell Signal & Trade Opportunity Analysis - خودرو بانک
Jobs Data: What is the dividend yield of Ligand Pharmaceuticals IncorporatedQuarterly Portfolio Report & Smart Allocation Stock Tips - khodrobank.com
Is Evolus Inc a strong candidate for buy and hold2025 Technical Overview & Verified Chart Pattern Trade Signals - خودرو بانک
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 12, 2025 - BioSpace
Zimmer Partners LP Increases Stake in Evolus, Inc. $EOLS - MarketBeat
Evolus, Inc. (NASDAQ:EOLS) Short Interest Update - MarketBeat
Evolus (NASDAQ:EOLS) Earns Buy Rating from BTIG Research - MarketBeat
EOLSEvolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - mx.advfn.com
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolus Inc Stock (EOLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stewart Brady | Director |
Aug 15 '25 |
Buy |
6.82 |
30,000 |
204,486 |
88,629 |
| MOATAZEDI DAVID | See Remarks |
Jun 13 '25 |
Sale |
10.05 |
111,323 |
1,119,141 |
381,509 |
| MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):